2016 Fiscal Year Final Research Report
Clinical research for the development of predictive biomarker useful for individualized radiotherapy in the treatment of lung cancer
| Project/Area Number |
26461896
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MASUDA Noriyuki 北里大学, 医学部, 教授 (70145465)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 肺癌 / 放射線治療 / バイオマーカー / 効果予測 / 個別化医療 |
|---|
| Outline of Final Research Achievements |
In adenocarcinoma of the lung, vimentin expression is prevalent and markedly up-regulated in micropapllary component (MPC), which might reflect the biological essence of poorer differentiation or dedifferentiation of MPC, and this might have a role in the acquisition and increase of invasiveness and consequent more malignant nature of MPC. In the 64 patients with stage III non-small cell lung cancer (NSCLC), the progression-free survival (PFS) was significantly shorter, and the overall survival (OS) was longer (6.3 vs. 9.5 months, p < .001, PFS, 37.1 vs. 21.1 months, p = 0.26, OS). Distant metastasis happened more frequently in the mutant EGFR than in the wild-type EGFR. In 39 patients received concurrent chemoradiotherapy with a humanized IgG1 monoclonal anti-EGFR antibody (nimotuzumab), the PFS was significantly better for patients with Sq than for those with Non-Sq. The low in field relapse rates may be attributed to the radio-sensitizing effect of anti-EGFR antibody.
|
| Free Research Field |
放射線腫瘍学
|
